Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein. Other Name(s): NVX-CoV2373, Novavax COVID-19 vaccine The Novavax coronavirus disease 2019 (COVID-19) vaccine is currently being studied to prevent coronavirus disease 2019 caused by the SARS-CoV-2 virus. Information from clinical trials is available at this time to support the use of COVID-19 vaccine, adjuvanted to prevent COVID-19. Novavax COVID-19 vaccine has not undergone the standard review to be approved by the FDA for use. However, the FDA has approved an Emergency Use Authorization (EUA) for the COVID-19 vaccine, Adjuvanted to allow use in individuals 12 years of age and older to prevent COVID-19 disease caused by SARS-CoV-2 infection. Talk to your doctor about the risks and benefits of receiving this vaccine. COVID-19 disease is caused by an infection with a coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory (lung) illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever, chills, cough, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea. The COVID-19 vaccine, adjuvanted will be given to you as an injection into the muscle. The COVID-19 vaccine , adjuvanted is given as a two doses given 3 weeks apart in individuals who have not previously been vaccinated with COVID-19. The FDA has also approved an EUA for the COVID-19 vaccine, adjuvanted to allow abooster dose for individuals 12 years or older to be given at least 2 months after receipt of any other COVID-19 vaccine. The FDA has also approved an EUA for the COVID-19 vaccine, adjuvanted to be given as an additional dose in individuals with altered immune system due to medical conditions or other drugs, at the discretion of their healthcare provider. Tell your vaccine provider about all of your medical conditions, including if you: In an ongoing clinical trial, theCOVID-19 vaccine, adjuvanted has been shown to prevent COVID-19 after the two-dose series. How long you are protected against COVID-19 is currently unknown. Side effects that have been reported with the COVID-19 vaccine, adjuvanted include: There is a remote chance that the COVID-19 vaccine, adjuvanted could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the COVID-19 vaccine, adjuvanted. Signs of a severe allergic reaction can include: Myocarditis and pericarditis have occurred in some people who have received the COVID-19 vaccine, adjuvanted. In most of these people, symptoms began within 10 days after getting the vaccine. The chance of having this occur is very low. You should seek medical attention right away if you have any of the following symptoms after receiving the vaccine: These may not be all the possible side effects of the COVID-19 vaccine, adjuvanted. Serious and unexpected side effects may occur. COVID-19 vaccine, adjuvanted is still being studied in clinical trials. No. the COVID-19 vaccine, adjuvanted does not contain SARS-CoV-2 and cannot give you COVID-19. When you get your dose, you will get a vaccination card. Remember to bring your card when you return for additional doses. The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. For more information about IISs, visit: https://www.cdc.gov/vaccines/programs/iis/about.html. No. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged an out-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19 vaccination. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured recipients). Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination Program requirements are encouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV. The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one year from the date of receiving the vaccine. To learn more about this program, visit http://www.hrsa.gov/cicp/ or call 1-855-266-2427. The American Society of Health-System Pharmacists, Inc. represents that this information about the Novavax COVID-19 vaccine was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are cautioned that the Novavax COVID-19 vaccine is not an approved vaccine for coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, but rather, is being investigated for and is currently available under an FDA emergency use authorization (EUA) to prevent COVID-19 in certain adults. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to the information, and specifically disclaims all such warranties. Readers of the information about the Novavax COVID-19 vaccine are advised that ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of this information. Readers are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information contained in this information is provided for informational purposes only. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. This information about the Novavax COVID-19 vaccine is not to be considered individual patient advice. Because of the changing nature of drug information, you are advised to consult with your physician or pharmacist about specific clinical use of any and all medications. This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use. The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care. AHFS® Patient Medication Information™. © Copyright, 2024. The American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP. Selected Revisions: October 15, 2023. This information does not replace the advice of a doctor. Ignite Healthwise, LLC disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use and Privacy Policy. Learn how we develop our content. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Ignite Healthwise, LLC.COVID-19 Vaccine, Adjuvanted
IMPORTANT WARNING:
What is COVID-19?
How is the COVID-19 vaccine, adjuvanted given?
What should you tell the person who is giving the vaccine?
What are the benefits of the COVID-19 vaccine, adjuvanted?
What are the risks of the COVID-19 vaccine, adjuvanted?
What should I do about side effects?
Will the COVID-19 vaccine, adjuvanted give me COVID-19?
Keep your vaccination card
Where will my vaccination information be recorded?
How can I learn more?
Can I be charged an administration fee for receiving the COVID-19 vaccine?
Where can I report cases of suspected fraud?
What is the Countermeasures Injury Compensation Program?
Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein.COVID-19 Vaccine, Adjuvanted